Literature DB >> 7714212

Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates.

R Q Warren1, M T Wong, G P Melcher, S P Blatt, P Cahn, H Perez, I Zapiola, M B Bouzas, G Muchinik, S A Anderson.   

Abstract

Utilizing peptides based on the V3 region of gp120, we undertook a serologic examination of human immunodeficiency virus type 1 (HIV-1)-infected individuals from Argentina to determine if prevalent HIV-1 isolates could be identified in this population. Our findings suggest that a similar pool of HIV-1 subgroup B isolates exists in both Argentina and the United States.

Entities:  

Keywords:  Americas; Antibodies; Antigens; Argentina; Biology; Developed Countries; Developing Countries; Examinations And Diagnoses; Hiv Serodiagnosis; Immunity; Immunologic Factors; Laboratory Examinations And Diagnoses; Latin America; North America; Northern America; Physiology; Research Report; South America; United States

Mesh：

Substances：

Year:  1995        PMID： 7714212      PMCID： PMC227971          DOI： 10.1128/jcm.33.2.481-483.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

Authors:  R Q Warren; S A Anderson; W M Nkya; J F Shao; C W Hendrix; G P Melcher; R R Redfield; R C Kennedy
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

2.  Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.

Authors:  N L Haigwood; P L Nara; E Brooks; G A Van Nest; G Ott; K W Higgins; N Dunlop; C J Scandella; J W Eichberg; K S Steimer
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees.

Authors:  R Q Warren; H Wolf; K R Shuler; J W Eichberg; R A Zajac; R N Boswell; P Kanda; R C Kennedy
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

4.  Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand.

Authors:  C P Pau; S Lee-Thomas; W Auwanit; J R George; C Y Ou; B S Parekh; T C Granade; D L Holloman; S Phillips; G Schochetman
Journal:  AIDS       Date:  1993-03       Impact factor: 4.177

5.  Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes.

Authors:  J Louwagie; F E McCutchan; M Peeters; T P Brennan; E Sanders-Buell; G A Eddy; G van der Groen; K Fransen; G M Gershy-Damet; R Deleys
Journal:  AIDS       Date:  1993-06       Impact factor: 4.177

6.  Genetic analysis of HIV-1 isolates from Brazil reveals presence of two distinct genetic subtypes.

Authors:  J Louwagie; E L Delwart; J I Mullins; F E McCutchan; G Eddy; D S Burke
Journal:  AIDS Res Hum Retroviruses       Date:  1994-05       Impact factor: 2.205

7.  Genetic heterogeneity of the V3 region of the HIV-1 envelope glycoprotein in Brazil. Brazilian Collaborative AIDS Research Group.

Authors:  K E Potts; M L Kalish; T Lott; G Orloff; C C Luo; M A Bernard; C B Alves; R Badaro; J Suleiman; O Ferreira
Journal:  AIDS       Date:  1993-09       Impact factor: 4.177

8.  Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjects.

Authors:  M T Wong; R Q Warren; S A Anderson; M J Dolan; C W Hendrix; S P Blatt; G P Melcher; R N Boswell; R C Kennedy
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

9.  [Molecular analysis of the principal neutralization epitope (V3 loop) of human immunodeficiency virus type 1 in Argentina].

Authors:  M Gómez Carrillo; C Piccardo; O Libonatti
Journal:  Rev Argent Microbiol       Date:  1992 Apr-Jun       Impact factor: 1.852

10.  Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.

Authors:  P L Nara; W G Robey; S W Pyle; W C Hatch; N M Dunlop; J W Bess; J C Kelliher; L O Arthur; P J Fischinger
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103
View more
  3 in total

1.  The Honduran human immunodeficiency virus type 1 (HIV-1) epidemic is dominated by HIV-1 subtype B as determined by V3 domain sero- and genotyping.

Authors:  C Lara; M Sällberg; B Johansson; I L de Rivera; A Sönnerborg
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

Review 2.  Recurrent CDC group IVc-2 bacteremia in a human with AIDS.

Authors:  R R Anderson; P Warnick; P C Schreckenberger
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

3.  Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progression.

Authors:  R Q Warren; M T Wong; G P Melcher; S P Blatt; I Zapiola; M B Bouzas; G Muchinik; S A Anderson; R C Kennedy
Journal:  Clin Diagn Lab Immunol       Date:  1995-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.